http://spherixnetwork.com/us-headquarters/ 2015-03-11T13:23:30+00:00 http://spherixnetwork.com/new-company/ 2015-03-11T13:24:25+00:00 http://spherixnetwork.com/new-insights-service-launched-for-highly-dynamic-pharmaceutical-markets/ 2015-08-13T09:27:19+00:00 http://spherixnetwork.com/biogens-tecfidera-and-other-orals-benefit-as-increasingly-risk-tolerant-neurologists-seek-to-arrest-multiple-sclerosis-ms-progression-sooner/ 2015-08-13T18:29:42+00:00 http://spherixnetwork.com/rheumatologists-plan-to-increase-their-use-of-pfizers-xeljanz-janssens-simponi-and-roches-actemra-in-the-next-month/ 2015-09-01T15:04:00+00:00 http://spherixnetwork.com/rheumatologists-report-widespread-adoption-and-anticipated-gains-for-celgenes-otezla-in-psoriatic-arthritis/ 2015-09-09T05:34:12+00:00 http://spherixnetwork.com/nephrologists-perceive-the-anemia-effects-of-keryxs-auryxia-to-be-favorable-but-market-penetration-at-six-months-post-launch-is-low/ 2015-09-13T07:43:45+00:00 http://spherixnetwork.com/glaxosmithklines-dominance-in-the-pulmonology-market-continues-with-the-recent-launch-of-their-new-combination-inhaler-for-asthma/ 2015-09-23T18:22:14+00:00 http://spherixnetwork.com/payers-expected-to-push-use-of-sandozs-glatopa-effectively-tying-neurologists-hands/ 2015-09-30T12:41:17+00:00 http://spherixnetwork.com/nephrologists-and-cardiologists-eager-for-new-agents-to-treat-hyperkalemia/ 2015-10-01T08:42:18+00:00 http://spherixnetwork.com/spherix-global-insight-gmbh-announces-acquisition-of-rare-insights-llc/ 2015-10-01T08:44:43+00:00 http://spherixnetwork.com/after-a-lackluster-launch-keryxs-auryxia-appears-to-be-moving-in-the-right-direction-according-to-spherix-global-insights-gmbh/ 2015-10-15T08:06:17+00:00 http://spherixnetwork.com/unmet-need-in-idiopathic-pulmonary-fibrosis-ipf/ 2015-12-01T09:19:36+00:00 http://spherixnetwork.com/relypsas-launch-of-veltassa-off-to-a-strong-start-according-to-us-nephrologists/ 2016-02-18T07:39:03+00:00 http://spherixnetwork.com/realtime-dynamix-renal-anemia-june-2016/ 2016-09-09T13:50:45+00:00 http://spherixnetwork.com/realtime-dynamix-hyperkalemia-june-2016/ 2016-09-09T13:53:06+00:00 http://spherixnetwork.com/a-waltz-with-taltz-dermatologists-report-early-adoption-of-ixekizumab-in-psoriasis/ 2016-09-09T13:53:27+00:00 http://spherixnetwork.com/neurologists-report-increasing-payer-pressure-for-disease-modifying-therapies-resulting-in-suboptimal-treatment-for-some-patients-with-multiple-sclerosis/ 2016-09-09T13:56:05+00:00 http://spherixnetwork.com/user-base-for-novartis-cosentyx-in-psoriatic-arthritis-significantly-expands-as-rheumatologists-report-high-satisfaction/ 2016-09-09T13:57:14+00:00 http://spherixnetwork.com/market-access-obstructs-newer-biologic-and-jak-adoption-in-rheumatoid-arthritis-2/ 2016-09-09T13:59:35+00:00 http://spherixnetwork.com/direct-to-consumer-campaigns-for-pfizers-xeljanz-abbvies-humira-and-amgens-enbrel-the-most-influential-with-ra-patients/ 2017-01-09T19:29:28+00:00 http://spherixnetwork.com/eli-lillys-taltz-gaining-ground-in-psoriasis-market-leaving-novartis-cosentyx-at-risk-in-2017-according-to-spherix-global-insights/ 2017-01-09T19:32:59+00:00 http://spherixnetwork.com/despite-an-increase-in-psoriatic-arthritis-patients-initiated-on-cosentyx-over-the-past-three-months-the-user-base-for-novartis-il-17-inhibitor-has-remained-stable/ 2017-01-09T19:33:15+00:00 http://spherixnetwork.com/studies-of-the-multiple-sclerosis-ms-market-highlight-the-increasing-penetration-of-oral-disease-modifying-therapies-dmts-into-first-line-position/ 2017-03-24T13:29:54+00:00 http://spherixnetwork.com/extended-fda-review-for-lillyincytes-olumiant-baricitinib-in-rheumatoid-arthritis-delays-market-entry-for-first-major-competitor-to-pfizers-xeljanz/ 2017-03-24T13:36:03+00:00 http://spherixnetwork.com/will-us-rheumatologists-follow-in-the-footsteps-of-dermatologists-for-adoption-of-eli-lillys-taltz/ 2017-03-24T13:41:02+00:00 http://spherixnetwork.com/the-battle-for-preferred-alternative-mechanism-biologic-in-crohns-disease-heats-up-as-launch-of-janssens-stelara-approaches-the-six-month-mark/ 2017-03-24T13:44:31+00:00 http://spherixnetwork.com/relypsas-veltassa-dodges-the-competition-bullet-as-fda-hands-astrazeneca-a-second-complete-response-letter-for-hyperkalemia-agent-zs-9/ 2017-07-26T17:14:26+00:00 http://spherixnetwork.com/pre-launch-intentions-for-sanofi-regenerons-dupixent-dupilumab-suggest-rapid-uptake-in-an-area-of-high-unmet-need/ 2017-07-26T17:17:19+00:00 http://spherixnetwork.com/roche-nabs-fda-approval-for-game-changing-therapy-for-the-treatment-of-multiple-sclerosis/ 2017-07-26T17:19:25+00:00 http://spherixnetwork.com/psoriasis-and-psoriatic-arthritis-markets-undergo-big-changes-as-il-17s-such-as-novartis-cosentyx-and-lillys-taltz-increase-penetration/ 2017-07-26T17:20:59+00:00 http://spherixnetwork.com/eu-rheumatoid-arthritis-landscape-poised-for-big-changes-as-rheumatologists-plan-for-the-adoption-of-eli-lillyincytes-olumiant-pfizers-xeljanz-and-regeneronsanofis-kevzara/ 2017-07-26T17:24:26+00:00 http://spherixnetwork.com/preference-persistency-and-positioning-for-lillys-taltz-in-psoriasis-highlight-a-potential-challenge-ahead-for-novartis-cosentyx-in-pso-and-psoriatic-arthritis/ 2017-07-26T17:26:21+00:00 http://spherixnetwork.com/keryxs-auryxia-and-vifor-fmcs-velphoro-slowly-gaining-share-in-the-phosphate-binder-market-while-big-shifts-in-ckd-mbd-loom-with-the-pending-introduction-of-amgens-parsabiv/ 2017-07-26T17:27:19+00:00 http://spherixnetwork.com/roches-ocrevus-penetrating-beyond-progressive-ms/ 2017-07-26T17:28:24+00:00 http://spherixnetwork.com/novartis-cosentyx-takes-the-wind-out-of-stelaras-sails-in-psoriatic-arthritis-market/ 2017-07-26T17:29:42+00:00 http://spherixnetwork.com/dupixent-delivers-and-sanofi-regeneron-ushers-in-a-new-era-of-atopic-dermatitis-ad-treatment/ 2017-07-26T17:32:36+00:00 http://spherixnetwork.com/janssens-stelara-overtakes-takedas-entyvio-as-the-leading-alternative-moa-in-crohns-disease-but-pressure-is-on-to-maximize-ibd-value-in-advance-of-pipeline-drugs-from-celgene-mongersen-ozanim/ 2017-07-26T17:33:27+00:00 http://spherixnetwork.com/novartis-cosentyx-and-eli-lillys-taltz-bring-disruption-to-the-psoriasis-market-as-il-17-share-increases-dramatically/ 2017-07-26T17:34:12+00:00 http://spherixnetwork.com/bms-orencia-plunges-into-the-fray-of-battle-for-alternative-moa-for-psoriatic-arthritis-with-recent-fda-approval-can-it-find-a-unique-space-to-play/ 2017-07-26T17:34:27+00:00 http://spherixnetwork.com/in-the-race-for-alternative-moa-biologic-in-crohns-disease-takedas-entyvio-maintains-the-lead-but-janssens-stelara-is-gaining-fast/ 2017-07-26T17:34:59+00:00 http://spherixnetwork.com/pfizers-inflectra-takedas-entyvio-and-janssens-simponi-projected-to-gain-ground-in-the-increasingly-competitive-ulcerative-colitis-market/ 2017-07-26T17:36:24+00:00 http://spherixnetwork.com/early-uptake-of-rochegenentechs-ocrevus-off-to-stellar-start-according-to-latest-quarterly-update-from-spherix-global-insights/ 2017-07-26T17:36:40+00:00 http://spherixnetwork.com/can-pharma-companies-expand-current-ankylosing-spondylitis-market-new-indication-non-radiographic-axial-spondyloarthropathy-nr-axspa-novartis-ucb-pharma-just-two-compani/ 2017-08-14T15:25:32+00:00 http://spherixnetwork.com/new-study-1000-dialysis-patients-reveals-significant-opportunity-improvement-hyperphosphatemia-highlights-potential-amgens-parsabiv/ 2017-08-14T15:26:58+00:00 http://spherixnetwork.com/janssens-tremfya-guselkumab-makes-debut-psoriasis-market-early-dermatologist-feedback-reveals-distinction-stelara-il-17-inhibitors-will-key-success/ 2017-08-14T15:28:36+00:00 http://spherixnetwork.com/likely-delay-janssens-sirukumab-sets-head-head-battle-rochegenentechs-actemra-sanofiregenerons-kevzara-us-rheumatoid-arthritis-market/ 2017-08-14T15:31:16+00:00 http://spherixnetwork.com/changes-afoot-management-ckd-mineral-bone-disorder-reinforced-clinical-practice-guideline-update-kdigo/ 2017-08-14T15:32:17+00:00 http://spherixnetwork.com/novartis-cosentyx-beginning-plateau-psoriatic-arthritis-us-rheumatologists-prepare-influx-non-tnf-agents-bms-orencia-pfizers-xeljanz-lillys-il-17-taltz/ 2017-08-15T14:35:51+00:00 http://spherixnetwork.com/uptake-sanofiregenerons-dupixent-atopic-dermatitis-strong-sales-representative-contact-rates-leave-something-desired/ 2017-08-21T20:07:13+00:00 http://spherixnetwork.com/us-gastroenterologists-may-thwart-uptake-new-biosimilars-pfizers-inflectra-mercksamsung-bioepis-renflexis-choosing-alternative-tnf-inhibitor-abbvies-humira/ 2017-08-30T18:41:41+00:00 http://spherixnetwork.com/early-launch-metrics-janssens-tremfya-may-lag-lillys-taltz-similar-post-launch-period-signs-indicate-new-il-23-inhibitor-poised-set-new-bar-efficacy-skin/ 2017-10-11T14:33:57+00:00 http://spherixnetwork.com/analysis-1000-psoriatic-arthritis-psa-patients-reveals-large-candidate-pool-pfizers-xeljanz-bms-orencia-eli-lillys-taltz/ 2017-10-11T14:35:18+00:00 http://spherixnetwork.com/first-class-ppms-indication-fueling-much-adoption-genentechs-ocrevus-insurance-coverage-issues-looming-stumbling-block/ 2017-10-11T14:35:42+00:00 http://spherixnetwork.com/fda-approval-mylans-glatiramer-acetate-will-turn-payer-pressure-tevas-copaxone-sandozs-glatopa/ 2017-10-11T14:38:59+00:00 http://spherixnetwork.com/despite-rheumatologist-reports-bms-orencia-preferred-non-tnf-agent-treating-rheumatoid-arthritis-pfizers-xeljanz-provides-steep-competition-actual-switching-patterns/ 2017-11-20T19:53:43+00:00 http://spherixnetwork.com/us-rheumatologists-teed-rapid-adoption-bms-orencia-psoriatic-arthritis-though-real-game-changer-come-approval-pfizers-xeljanz/ 2017-11-20T19:56:18+00:00 http://spherixnetwork.com/us-rheumatologists-report-use-biologicjak-monotherapy-rheumatoid-arthritis-greatest-pfizers-xeljanz-rochegenentechs-actemra-sanofiregenerons-recen/ 2017-11-20T19:58:10+00:00 http://spherixnetwork.com/janssens-stelara-novartis-cosentyx-take-cake-psoriasis-patients-switch-biologicotezla-agents-according-recent-audit-nearly-1000-recently-switched-psor/ 2017-11-20T20:00:15+00:00 http://spherixnetwork.com/renal-anemia-market-cusp-change-beginning-fda-approval-keryx-biopharmaceuticals-auryxia-treatment-iron-deficiency-anemia-ida-adults-chronic-kidney-di/ 2017-11-20T20:01:02+00:00 http://spherixnetwork.com/cardiologists-continue-lag-nephrologists-comes-adoption-viforrelypsas-veltassa-hyperkalemia-prescribers-specialties-report-mounting-market-access-pressure/ 2017-11-20T20:06:22+00:00 http://spherixnetwork.com/advanced-practice-providers-treat-significantly-multiple-sclerosis-patients-monoclonal-antibody-disease-modifying-therapies-compared-neurologists-us/ 2017-11-20T20:07:24+00:00